Prepair 500+
Gene: MPI
CDG Ib is clinically distinct from most other CDGs by the lack of significant central nervous system involvement. The predominant symptoms are chronic diarrhea with failure to thrive and protein-losing enteropathy with coagulopathy. Some patients develop hepatic fibrosis. CDG Ib is also different from other CDGs in that it can be treated effectively with oral mannose supplementation, but can be fatal if untreated.
HGNC approved symbol/name: MPI
Is the phenotype(s) severe and onset <18yo? Yes
Treatments available: Yes - Mannose. One of the few treatable subtypes of CDGs with proven effect of oral mannose, recommended by consensus guidelines (PMID: 32266963)
Known technical challenges? No
Gene reported in 3 independent families: YesCreated: 29 Jan 2025, 2:31 p.m. | Last Modified: 29 Jan 2025, 2:31 p.m.
Panel Version: 1.1357
Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal
Phenotypes
Congenital disorder of glycosylation, type Ib, MIM# 602579
Publications
Gene: mpi has been classified as Green List (High Evidence).
Phenotypes for gene: MPI were changed from Congenital disorder of glycosylation, type Ib, 602579 (3) to Congenital disorder of glycosylation, type Ib, MIM# 602579
Publications for gene: MPI were set to
gene: MPI was added gene: MPI was added to Prepair 500+. Sources: Mackenzie's Mission,Expert Review Green Mode of inheritance for gene: MPI was set to BIALLELIC, autosomal or pseudoautosomal Phenotypes for gene: MPI were set to Congenital disorder of glycosylation, type Ib, 602579 (3)